Drug Profile
Olmutinib - Hanmi Pharmaceutical
Alternative Names: BI 1482694; EMSI; HM 61713B; HM61713; Olita; ZL-2303Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class 2 ring heterocyclic compounds; Antineoplastics; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Non-small cell lung cancer
Most Recent Events
- 08 Dec 2020 Boehringer Ingelheim terminates the phase II ELUXA-1 trial for Non-small cell lung cancer in USA, Australia, Canada, Malaysia, Philippines, South Korea, Spain, Italy, Germany and Taiwan (NCT02485652)
- 12 Aug 2020 Hanmi Pharmaceutical terminates a phase Ib trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (PO) (NCT04510415)
- 31 Jul 2019 Konkuk University Medical Center and Hanmi Pharmaceutical complete a phase II trial for Non-small cell lung cancer (Inoperable/unresectable, Late-stage disease, Second-line therapy or greater) in South Korea (PO) (NCT03228277)